ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325 - Top-Institutions - MDSpire

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

June 26, 2026

Dana-Farber

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
#2

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Oncology
#3

Peter MacCallum Cancer Centre

Melbourne, Victoria
Key Differentiators
- Oncology
#4

Leon Berard Centre

Lyon, Auvergne-Rhône-Alpes
Key Differentiators
- Oncology